Telehealth Giant Hims & Hers Marks Five Years as a Public Company
New York, Tuesday, 18 August 2026.
Ringing the NYSE bell for its fifth listing anniversary, Hims & Hers highlighted massive growth, with annual revenue surging from $272 million to $2.3 billion since 2021.
NYSE Bell Ringing Ceremony
On Monday, 17 August 2026, Hims & Hers Health (NYSE: HIMS) celebrated its fifth anniversary as a public company by ringing the opening bell at the New York Stock Exchange [1][4]. The ceremony marked exactly five years since the telehealth provider’s initial market debut via a merger with Oaktree Acquisition Corp. in 2021 [4][5]. CEO Andrew Dudum attended the event to declare the company’s entry into its “next phase of growth” following the milestone [5][7].
Current Market Status
As of 18 August 2026, the stock price for Hims & Hers Health was recorded at $28.33 [2]. The company operates within the Health Care sector and specifically in the Health Care Providers & Services industry [2]. Despite recent volatility, the company maintains its listing on the NYSE, where icons and disruptors converge to shape market futures [1].
Financial Trajectory and Profitability
Financial data indicates substantial expansion since the company’s public listing, with annual revenue growing from $272 million in 2021 to $2.3 billion in 2025 [5][7]. This surge represents a compound annual growth rate of nearly 64% over the period [5]. The revenue increase from 2021 to 2025 can be expressed as a percentage growth of 745.588 [5][7].
Operational Efficiency
Hims & Hers achieved positive operating profit in both 2024 and 2025, marking a shift from initial operating losses post-IPO [5][7]. Operational milestones include the implementation of an AI-native care platform that reportedly tripled customer messaging volume [5]. Additionally, the platform reduced nonclinical support workload by approximately 50%, enhancing technical efficiency [7].
Strategic Expansions and Partnerships
In June 2026, the company completed a $1.2 billion acquisition of Australian telehealth provider Eucalyptus [5][7]. This move expanded operations into Australia, the U.K., Germany, Canada, and Japan, contributing to international revenue of $131 million in Q2 2026 [5]. Furthermore, a partnership with Novo Nordisk to offer branded Wegovy and Ozempic was revived in March 2026 after a termination in June 2025 [5][7].
Market Sentiment and Volatility
Retail sentiment for HIMS on Stocktwits shifted to ‘bearish’ as of 16 August 2026, accompanied by a 1,020% surge in 24-hour message volume [5][7]. The stock has declined 39% over the past year and 12% since 1 January 2026 [5]. This volatility follows a period where the share price had previously reached a record high of $68.74 in February 2025 [5][7].
Long-Term Projections
Looking ahead, Hims projects 2030 targets of at least $6.5 billion in annual revenue and $1.3 billion in adjusted EBITDA [5][7]. Fiscal.ai projects 2026 revenue to reach $3.2 billion, though operating losses are expected due to elevated investment [5]. CEO Andrew Dudum has described the strength of the company’s relationship with Novo Nordisk as “extremely” robust amidst these projections [5].